Drug Trial Radar · NCT06525649
A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042
Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Aug 21, 2024
Primary completion
Jun 26, 2025
Study completion Jun 26, 2025
Sponsor
- Lead sponsor
- NeuroPro Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- The Epilepsy Study Consortium
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.
Conditions
- Photosensitive Epilepsy
- Epilepsy
Interventions
NPT 2042Drug
NPT 2042 is a new drug being developed as an anti-seizure treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the change in the adjudicated SPR (standard photosensitivity range)Time frame: Through study completion, an average of 4 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trials, Inc. (CTI)
Little Rock, Arkansas
Idaho Comprehensive Epilepsy Center
Boise, Idaho
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.